Canadian Journal of Gastroenterology (Jan 2009)

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy

  • Eric M Yoshida,
  • Morris Sherman,
  • Vincent G Bain,
  • Curtis L Cooper,
  • Marc Deschênes,
  • Paul J Marotta,
  • Samuel S Lee,
  • Mel Krajden,
  • Helga Witt-Sullivan,
  • Robert J Bailey,
  • Christopher Usaty,
  • Kevork Peltekian,
  • the Canadian Pegasys Study Group

DOI
https://doi.org/10.1155/2009/470532
Journal volume & issue
Vol. 23, no. 3
pp. 180 – 184

Abstract

Read online

BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.